US bioeconomy policy in September 2026 still has no replacement for Executive Order 14081, the September 2022 directive that organized federal biotechnology strategy, eighteen months after its revocation on March 14, 2025. The operative instruments are legacy programs and a 2025 research-security order, while an updated Coordinated Framework was never released, per regulatory filings.
What happened to the 2022 bioeconomy executive order?
Executive Order 14081, "Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy," was published September 12, 2022 and directed USDA, EPA, and FDA to modernize the regulation of biotechnology products and to build coordinated agency infrastructure. On March 14, 2025, President Trump signed Executive Order 14236 rescinding 19 prior executive actions, among them EO 14081, as Legal 500 reported. The accompanying White House fact sheet criticized the order on the ground that it "funneled Federal resources into radical biotech and biomanufacturing initiatives."
The revocation mattered because EO 14081 had assignments in flight. The agencies had been directed to identify gaps in the 1986 Coordinated Framework for the Regulation of Biotechnology and drafted a reform plan; an updated framework was expected in December 2024, per the Legal 500 account, but the agencies never released it. No successor order restating a whole-of-government bioeconomy strategy has been issued since.
What is the active biosecurity instrument now?
The current administration's principal biology directive is Executive Order 14292, "Improving the Safety and Security of Biological Research," signed May 5, 2025. Per the order, it states that "dangerous gain-of-function research on biological agents and pathogens has the potential to significantly endanger the lives of American citizens," directs an end to federal funding for such research by foreign entities in countries of concern, requires revision of the 2024 dual-use research oversight policy within 120 days, and mandates a strategy within 180 days to track non-federally funded gain-of-function research.
The orientation is defensive rather than industrial: oversight, funding restrictions, and enforcement mechanisms including grant ineligibility, rather than biomanufacturing capacity or market creation. For companies in the bioeconomy supply chain, that means the federal posture toward their sector is currently defined more by research-security rules than by the growth agenda of the revoked 2022 order.
Which legacy programs still carry the agenda?
Day-to-day infrastructure built under the 2022 order continues to operate. USDA, EPA, and FDA maintain the Unified website for Biotechnology Regulation that gives developers a single point of contact for regulatory questions across agencies, and that platform's supporting paperwork remains active — a December 2024 Federal Register notice describes the web form through which developers "submit inquiries about a particular product and promptly receive a single, coordinated response" on federal regulatory review.
Data infrastructure likewise persists. A 13-agency interagency working group's report, "Vision, Needs, and Proposed Actions for the Data for the Bioeconomy Initiative," released in January 2024 per the Department of Energy, outlines the data landscape supporting US biotechnology and proposes actions for "advancing biotechnology; improving U.S. data infrastructure and accessibility" and growing the bioeconomy across sectors. Agency funding lines in biomanufacturing and bioenergy continue under existing appropriations.
What has not returned is the coordinating signal. Whether the administration issues a new bioeconomy strategy, releases the shelved Coordinated Framework update, or leaves the sector to piecemeal agency action is not yet disclosed. For now, the operative fact for industry planners is that the 2022 framework is gone, its replacement has not arrived, and the programs it created run on institutional momentum.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
